- li>
- li>
- li>
- li>
- li>
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | -0.20 | -0.03 | 586.98 |
| EPS, GAAP | -0.21 | -0.04 | -0.04 |
| Consensus Estimate | -0.15 | -0.09 | 64.76 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | -0.45 | 1.71 | -126.53 |
| EPS, GAAP | -0.48 | 1.64 | -129.32 |
| Consensus Estimate | -0.32 | 1.63 | -119.34 |
| BMRN | Industry Average | |
| P/E (TTM) | 0.00 | NA |
| P/E (Forward) | 0.00 | NA |
| PEG Ratio | 0.00 | 2.17 |
| Price/Sales | 9.67 | 4.18 |
| Beta | 0.91 | 0.62 |
| 5/9/2012 | CFO Moves: Tyco; Ramtron; BioMarin (WSJ.com) |
| 3/27/2012 | Canaccord dives into the biotechs. (The Motley Fool) |
![[sm061210things]](http://s.wsj.net/public/resources/images/PF-AC562_sm0612_C_20120514113337.jpg)
![[sm0612wedding4]](http://s.wsj.net/public/resources/images/PF-AC579_sm0612_C_20120515172853.jpg)
![[sm0612strat]](http://s.wsj.net/public/resources/images/PF-AC580_sm0612_C_20120515180019.jpg)
![[sm0612roi]](http://s.wsj.net/public/resources/images/PF-AC573_sm0612_C_20120515125902.jpg)